Linear and Branched Glyco-Lipopeptide Vaccines Follow Distinct Cross-Presentation Pathways and Generate Different Magnitudes of Antitumor Immunity

Abstract

These findings have important implications for the development of effective GLP based immunotherapeutic strategies against cancers.